CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?
This article was originally published in The Tan Sheet
Executive Summary
CFSAN will begin sending letters to companies notifying them when an adverse event report involving one of their products has been received on or after Sept. 16
You may also be interested in...
Trans Fat Labeling Should Help Product Comparisons, FDAer Claims
FDA will conduct an "educational campaign" over the next couple of years to teach consumers about trans fat and what to consider when buying products that contain the substance, according to San Francisco District Office Public Affairs Specialist Janet McDonald, PhD
Mandatory AE Information Requirements Needed For CAERS Filings – AHPA
Adverse event reports should be required to contain certain information before being filed in the CFSAN Adverse Events Reporting System (CAERS), AHPA says in an Oct. 21 letter to the agency
FDA Dietary Supplement Claims Oversight Will Be “More Aggressive” – Troy
FDA plans to intensify enforcement of inappropriate structure/function claims, Chief Counsel Daniel Troy asserted at the Food & Drug Law Institute educational conference April 16-17